Pharmacologic treatment and SUDEP risk: A nationwide, population-based, case-control study.

Neurology · 2020 · PMC7682832 · PMID 32967928

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

showed a trendno p-value reported

Other monotherapies, notably valproic acid, phenytoin, and oxcarbazepine, showed a nonsignificant trend for a reduced SUDEP risk, whereas topiramate showed a trend in the other direction, with an OR of 3.32 for increased SUDEP risk, which may warrant further investigation.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.